Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

AIMS: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist tha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Obes Metab
Päätekijät: Heerspink, Hiddo J. L., Andress, Dennis L., Bakris, George, Brennan, John J., Correa‐Rotter, Ricardo, Dey, Jyotirmoy, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John, Perkovic, Vlado, Tobe, Sheldon, Wigderson, Melissa, Parving, Hans‐Henrik, de Zeeuw, Dick
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2018
Aiheet:
Clinical Trial Design
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969254/
https://ncbi.nlm.nih.gov/pubmed/29405626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13245
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia